FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening
Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival
Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease
Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate
Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen
Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months
LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I
ASCO Releases Three Guidelines For Cancer Survivorship Care
NCI CTEP Approved Trials For the Month of April
Trending Stories
- Narjust Duma named associate director of the Cancer Care Equity Program at DFCI, Harvard Medical School
- Robert Stone: City of Hope aims to transform cancer care nationally through new models, partnerships
- Biden commits to creating “ARPA-H” research body in visit to Ohio State
- Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- The Cancer Letter gets a new website
You may have noticed that things are looking different around here - Abecma receives FDA approval for multiple myeloma
